The FY20 Defense Appropriations Act provides funding to the Department of Defense Kidney Cancer Research Program (KCRP) to support research of exceptional scientific merit in the area of kidney cancer. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
The FY20 KCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.
Applications submitted to the FY20 KCRP Idea Development Award mechanism are encouraged to address one or more of the following Areas of Emphasis:
- Treatments/Survivorship
- Basic/Translational Science
- Diagnostics/Prognostics/Biomarkers/Surveillance
- Population-Based Studies
- Noninvasive Interventions
- Surgical Interventions
- Therapeutic Development
- Understanding and Managing Toxicity
- Survivorship and Patient Experience
- Genetics
- Chromatin and Gene Regulation
- Metabolism
- Microenvironment and Immunology
- Environmental Exposures (and/or Deployment-Related Exposures)
- New Disease Model Systems
- Rare Kidney Cancers
- Mechanism of Response and Resistance
- Prognosis
- Biomarker Development
- Novel Imaging Technologies
- Liquid Biopsy
- Microbiome
- Disease Disparities
- Screening and Early Detection
- Surveillance
- Outcome/Population-Based Studies
- Environmental Exposures (and/or Deployment-Related Exposures)
- Disease Disparities
https://cdmrp.army.mil/funding/kcrp
Clinical Consortium Award – Letter of Intent Due September 2, 2020
Independent Investigators at or above the level of Assistant Professor (or equivalent)
- Supports the expansion of a consortium that will facilitate rapid execution of collaborative clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease impact of kidney cancer
- Funds may not be used for research or development of clinical protocols
- Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of kidney cancer are encouraged
- Up to two (2) Clinical Trial Sites will be selected and be jointly responsible for proposing, selecting, and conducting trials within the existing Kidney Cancer Research Consortium
- Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer
- The consortium is expected to achieve financial self-sufficiency, such that operating can continue after the award period ends.
- Maximum funding of $600,000 for direct costs (plus indirect costs)
- Maximum period of performance 2 years
- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement
Idea Development Award - Letter of Intent Due September 2, 2020
Established Investigators:
Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree
Early Career Investigators:
Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible
- Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer
- Innovation and Impact are the most important review criteria
- Different funding options, based on the scope of the proposed research, are available with compelling justification.
- Preliminary data are required.
- Clinical trials not allowed
Early Detection Studies Option:
- Maximum funding of $650,000 in direct costs (plus indirect costs)
- Maximum period of performance 3 years
- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement
Population Science and Prevention Studies Option:
- Maximum funding of $2 million in direct costs (plus indirect costs)
- Maximum period of performance 4 years
- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement
Postdoctoral and Clinical Fellow Award – Letter of Intent Due September 2, 2020
Must have completed requirements for Ph.D. and/or M.D.
Must be in the laboratory or clinical setting where proposed research will be performed.
Must have no more than 4 years of postdoctoral and/or mentored clinical research experience
Investigators in non-postdoctoral and/or clinical fellow positions are not eligible.
- Supports research opportunities focused on kidney cancer for individuals in the early stages of their careers
- A designated mentor who is an experienced kidney cancer researcher is required.
- Clinical trials are not allowed.
- Maximum funding of $195,000 for direct costs (plus indirect costs)
- Maximum period of performance 3 years
- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Help Desk
301-682-5507
help@eBrap.org